The Cancer of the Pancreas Screening-5 CAPS5)Study
Key facts
- Where
- Ann Arbor, Baltimore, Boston, Cleveland, New Haven, New York, Philadelphia, and Pittsburgh, United StatesSee the 9 sites
- Phase
- Phase 3
Where in United States
- University of MichiganAnn Arbor, United StatesTaking people
- Johns Hopkins HospitalBaltimore, United StatesTaking people
- Dana Farber Cancer Center, Harvard UniversityBoston, United StatesTaking people
- Case Comprehensive Cancer Center, Case Western Medical ReserveCleveland, United StatesTaking people
- Yale UniversityNew Haven, United StatesTaking people
- Columbia University Medical CenterNew York, United StatesTaking people
- NYU Langone Medical CenterNew York, United StatesTaking people
- University of PennsylvaniaPhiladelphia, United StatesTaking people
- University of PittsburghPittsburgh, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Johns Hopkins University
- Trial code
- NCT02000089
- Record updated
- 22 October 2026
- Original description
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.Read full original descriptionShow less
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Inclusion: Hereditary Pancreatitis or; Peutz-Jeghers Syndrome or; Strong family history of pancreas cancer on one side of the family tree or; Confirmed germline mutation carrier (BRCA2, FAMMM (CDKN2A/p16), PALB2, BRCA1, ATM, HNPCC, Lynch Syndrome (hMLH1, hMSH2, PMS2, hMSH6, EpCAM) PRSS1, PRSS2, R122H, N291l, SPINK1, CFTR; Endoscopic evaluation of pancreas scheduled.
Exclusion: Prior surgery that prevent optimal endoscopic ultrasound such as partial or complete gastrectomy with Bilroth or Roux-en-Y anastomosis; Medical comorbidities or coagulopathy that contraindicate endoscopy; Stricture or obstruction in the upper GI tract that does not allow passage of the echoendoscope; Poor performance status; Inability to provide informed consent; Pregnancy.